Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

Anti-inflammatory drug celecoxib reacts with protein and induces liver cancer cells to commit suicide

FDA nod for hepatitis C drug

FDA nod for hepatitis C drug

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Roche initiates TB-403 Phase Ib/II study in glioblastoma multiforme

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

Merck receives FDA approval for Victrelis to treat chronic hepatitis C

TFAH applauds HHS for new strategic approach to prevent viral hepatitis

TFAH applauds HHS for new strategic approach to prevent viral hepatitis

Majority of urban NYC women with hepatitis B do not receive education, subsequent care

Majority of urban NYC women with hepatitis B do not receive education, subsequent care

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

BioAlliance Pharma enters license deal with Sosei to commercialize Loramyc in Japan

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Sosei acquires rights to Loramyc in Japan from BioAlliance Pharma

Merck launches 'Hope Against Hepatitis C' education program

Merck launches 'Hope Against Hepatitis C' education program

H. pylori DNA may help treat severe colitis

H. pylori DNA may help treat severe colitis

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

Missouri S&T's cottony glass material may heal open wounds

Missouri S&T's cottony glass material may heal open wounds

New antioxidant may prevent liver damage in chronic alcoholics

New antioxidant may prevent liver damage in chronic alcoholics

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Antiviral Drugs Advisory Committee recommends FDA to approve telaprevir for hepatitis C

Researchers discover possible role of SCCA in breast cancer progression

Researchers discover possible role of SCCA in breast cancer progression

Curis reports first quarter net loss of $6.8 million

Curis reports first quarter net loss of $6.8 million

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

Hepatitis B virus rebound common in patients receiving nucleoside analogs for chronic hepatitis B

IL28B gene plays a key role in spontaneous HCV clearance in infants

IL28B gene plays a key role in spontaneous HCV clearance in infants

New screening marker can detect pancreatic cancer

New screening marker can detect pancreatic cancer

Children, adolescents with liver disease may not benefit from vitamin E or metformin

Children, adolescents with liver disease may not benefit from vitamin E or metformin

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.